OMEROS CORPORATION

Address

201 Elliott Avenue West
SEATTLE, WA, -

Information

DUNS: 33364923
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Development of NMUR2 Antagonists as Novel Analgesics

    Amount: $1,041,859.00

    DESCRIPTION (provided by applicant): Pain affects over 100 million Americans annually. Opioids are the primary drugs that can treat pain. However, these drugs produce severe and unwanted side effects, ...

    SBIRPhase II2012Department of Health and Human Services
  2. Monoclonal Antibodies for Orphan GPCRs in the CNS

    Amount: $697,020.00

    DESCRIPTION (provided by applicant): Monoclonal Antibodies for Orphan GPCRs in the CNS GPCRs comprise a large family of structurally related membrane proteins with critical functions in neurobiology. ...

    SBIRPhase I2012Department of Health and Human Services
  3. MASP-2 Antibodies for Diabetic Neuropathy

    Amount: $193,002.00

    DESCRIPTION (provided by applicant): The overall objective of the MASP-2 program is to develop a monoclonal antibody that blocks the function of MASP-2, in order to treat microvascular complications a ...

    SBIRPhase I2012Department of Health and Human Services
  4. Development of MASP-2 MoAbs for the treatment of diabetic nephropathy

    Amount: $198,383.00

    DESCRIPTION (provided by applicant): The long-term objective of this application is to develop a MASP-2 blocking monoclonal antibody as a therapeutic agent to prevent and treat complications of diabet ...

    SBIRPhase I2010Department of Health and Human Services
  5. MASP-2 Therapy for Macular Degeneration

    Amount: $660,672.00

    DESCRIPTION (provided by applicant): The overall goal is to develop monoclonal antibody (MoAb)-based compounds capable of blocking human MASP-2 function as potential therapeutic agents for the treatme ...

    SBIRPhase II2010Department of Health and Human Services
  6. A novel therapeutic target for OA that restores IGF-1 responses

    Amount: $148,400.00

    DESCRIPTION (provided by applicant): The long-term goal of our research is to develop an effective treatment for osteoarthritis (OA). There is no effective treatment for OA, and the potential market f ...

    SBIRPhase I2009Department of Health and Human Services
  7. A novel therapeutic target for OA that restores IGF-1 responses

    Amount: $334,600.00

    DESCRIPTION (provided by applicant): This is a revision application under NOT-OD-09-058 entitled NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications. In this ...

    SBIRPhase I2009Department of Health and Human Services
  8. Universal High Throughput GPCR Screening Assay

    Amount: $476,876.00

    DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCR) are a family of cell surface proteins involved in mediating many of the biological actions of neurotransmitters in the brain. It ...

    SBIRPhase I2009Department of Health and Human Services
  9. Novel therapy for osteoporosis

    Amount: $193,888.00

    DESCRIPTION (provided by applicant): The long-term goal of our research is to develop a novel treatment for osteoporosis that will stimulate bone formation. An estimated 10 million Americans over the ...

    SBIRPhase I2009Department of Health and Human Services
  10. Development of Novel Analgesics Targeting a Brain GPCR

    Amount: $107,050.00

    DESCRIPTION (provided by applicant): Chronic pain affects over 100 million Americans annually. Opiates are the primary drugs that can treat chronic pain. However, these drugs produce severe unwanted s ...

    SBIRPhase I2008Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government